Economic impact of antimicrobial resistance.

McGowan, J. E.

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Economic impact of antimicrobial resistance.

Published Date:

2001 Mar-Apr

Source:

Emerg Infect Dis. 7(2):286-292.

[PDF-66.32 KB]

Details:

Personal Authors:

McGowan, J. E.

Keywords:

[+]

Description:

One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Supporting Files:

	11294725.nxml	text/plain
	license.txt	text/plain

No Related Documents.

You May Also Like:

A public health perspective on antimicrobial resistance diagnostics : meeting summary and opportunities to address challenges

Corporate Author:

Centers for Disease Control and Prevention (U.S.). AdvaMedDx..

Published:

March 2016

Description:

On December 4, 2015, CDC’s Division of Healthcare Quality Promotion’s Office of Antimicrobial Resistance (OAR) and AdvaMedDx hosted an all-day meeting with industry leaders to forecast the future development of diagnostic tests and look for solut...

File Type:

[PDF - 412.36 KB]
Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridioides difficile infection in US hospitals

Personal Author:

Scott, R. Douglas; Slayton, Rachel B.; Lessa, Fernanda C.; Baggs, James; Culler, Steven D.; McDonald, L. Clifford; Jernigan, John A.;

Published:

Jan 22 2019

Source:

Antimicrob Resist Infect Control. 8

Description:

Backgound : Economic evaluations of interventions to prevent healthcare-associated infections in the United States rarely take the societal perspective and thus ignore the potential benefits of morbidity and mortality risk reductions. Using new Depar...

File Type:

[PDF - 691.36 KB]
Reference Group Choice and Antibiotic Resistance Outcomes

Personal Author:

Kaye, Keith S.; Engemann, John J.; Mozaffari, Essy; Carmeli, Yehuda;

Published:

Jun 2004

Source:

Emerg Infect Dis. 10(6):1125-1128.

Description:

Two types of cohort studies examining patients infected with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) were contrasted, using different reference groups. Cases were compared to uninfected patients a...

File Type:

[PDF - 71.45 KB]
A Public health action plan to combat antimicrobial resistance; Domestic issues; Part 1

Corporate Author:

United States, Interagency Task Force on Antimicrobial Resistance.

Published:

2001

Description:

The Interagency Task Force on Antimicrobial Resistance is co-chaired by the Centers for Disease Control and Prevention, Food and Drug Administration, and the National Institutes of Health. It also includes the Agency for Healthcare Research and Quali...

File Type:

[PDF - 114.23 KB]
Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery.

Personal Author:

Zanetti, G.; Goldie, S. J.; Platt, R.;

Published:

2001 Sep-Oct

Source:

Emerg Infect Dis. 7(5):820-827.

Description:

Routine us of vancomycin for perioperative prophylaxis is discouraged, principally to minimize microbial resistance to it. However, outcomes and costs of this recommendation have not been assessed. We used decision-analytic models to compare clinical...

File Type:

[PDF - 75.90 KB]